Kirwan J F, Constable P H, Murdoch I E, Khaw P T
Department of Epidemiology and International Eye Health Institute of Ophthamology, London, UK.
Eye (Lond). 2003 Mar;17(2):207-15. doi: 10.1038/sj.eye.6700306.
Beta radiation has a long history as a treatment modality in ophthalmology. It is a convenient and practical method of applying radiation and has the advantage of minimal tissue penetration. There has been a recent resurgence in the use of beta radiation in other areas in medicine, such as the prevention of restenosis after coronary artery stenting. Beta radiation has been shown in vitro and in vivo to inhibit proliferation of human Tenon's fibroblasts, which enter a period of growth arrest but do not die. Effects on the cell cycle controller p53 have been shown to be important in this process. In ophthalmology, beta radiation has been used widely for the treatment of pterygium and is under evaluation for treatment of age-related macular degeneration and for controlling wound healing after glaucoma drainage surgery. In this latter role, beta radiation may be particularly appropriate for use in developing countries to improve the results of trabeculectomy while potentially avoiding some of the side effects of other antimetabolites.
β射线作为眼科治疗手段已有很长历史。它是一种便捷实用的辐射应用方法，具有组织穿透性极小的优点。近期，β射线在医学其他领域的应用有所复兴，比如预防冠状动脉支架置入术后再狭窄。体外和体内研究均表明，β射线可抑制人眼球筋膜成纤维细胞的增殖，这些细胞进入生长停滞期但不会死亡。在此过程中，对细胞周期调控因子p53的影响已被证明很重要。在眼科，β射线已广泛用于治疗翼状胬肉，目前正在评估其用于治疗年龄相关性黄斑变性以及控制青光眼引流术后伤口愈合的效果。在后一种作用中，β射线可能特别适合在发展中国家使用，以改善小梁切除术效果，同时有可能避免其他抗代谢药物的一些副作用。
